# Bulk and Single-Cell Transcriptomics Reveal That SCO2 Drives Psoriasis via Activating CCR7+ Dendritic Cell

## TL;DR

This study shows that the protein SCO2 plays a key role in psoriasis by linking keratinocyte metabolism to immune responses involving dendritic cells.

## Contribution

The study identifies SCO2 as a novel immunometabolic driver of psoriasis through its role in activating CCR7+ dendritic cells.

## Key findings

- SCO2 is upregulated in psoriatic lesions and promotes keratinocyte migration and lactate retention.
- SCO2-high keratinocytes interact with CCR7+ dendritic cells via MIF-(CD74 + CD44) to drive T cell priming.
- Targeting SCO2 may disrupt IL-23-mediated inflammation and serve as a biomarker for psoriasis.

## Abstract

Metabolic reprogramming is a hallmark of psoriasis, yet the contribution of lactate metabolism to keratinocyte-mediated immune dysregulation remains undefined. Through integrated bulk and single-cell RNA sequencing, validated by immunofluorescence and metabolic assays, we identified the mitochondrial protein SCO2 as a key pathogenic hub gene upregulated in psoriatic lesions. Functionally, SCO2 overexpression promoted keratinocyte migration and triggered a metabolic shift characterized by mitochondrial pyruvate accumulation and intracellular lactate retention. Single-cell analysis further revealed that SCO2-high keratinocytes establish pathogenic crosstalk with CCR7+ dendritic cells via MIF-(CD74 + CD44) interactions, wherein these CCR7+ dendritic cells serve as the primary source of IL-23 and co-stimulatory signals (CD80/CD86) to drive robust T cell priming. Our findings highlight SCO2 as a pivotal immunometabolic switch linking keratinocyte metabolism to adaptive immunity. Targeting SCO2 offers a novel strategy to disrupt the keratinocyte-driven recruitment of CCR7+ DCs, thereby attenuating the IL-23-mediated inflammatory cascade. Furthermore, SCO2 may serve as a potential biomarker for metabolic dysregulation in psoriatic lesions.